
Radiopharm (ASX:RAD, NASDAQ:RADX) Advances with New Trials, Key Partnerships and Promising Data
Highlights Radiopharm secured a USD 5mn investment from Lantheus Holdings, making Lantheus the company’s largest shareholder. The Phase 2b trial of RAD 101 has advanced, with the first patient dosed for suspected recurrent brain metastasis. Radiopharm has …